3D Systems & Antleron collaborate on 3D bioprinting

US-based OEM 3D Systems and Belgian biotech company Antleron have announced a collaboration which the companies hope will play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry and developing regenerative products for personalised patient care.

The collaborative relationship between the two companies looks to address solutions for medical device and advanced therapy medicinal product applications. The goal is to establish a flexible, scalable Digital Factory approach, which includes digital monitoring and quality control for risk mitigation. 

For example, one technique being looked at seeks to advance the way cells and tissue are grown to enable the transition from a static 2D to bioreactor-based 3D cell culture. This can lead to new ways to manufacture functionalised medical implants, vaccines, cell therapies, and living tissues.

"The vision of Antleron is to sustainably bring living therapies into the clinic," said Jan Schrooten, Antleron CEO. "3D printing is key to this endeavour, and we are eager to collaborate with 3D Systems and its experts. I look forward to the pioneering solutions we'll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach."

"3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilising the 3D Systems' state of the art printing platforms and materials," said Chuck Hull, co-founder and chief technology officer, 3D Systems. "As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields."

3D Systems and Antleron will exhibit what is in store for next-generation medical applications at Formnext 2019 to be held November 19-22.

Back to Homepage

Back to Healthcare